Nova Eye Medical (EYE) Discussion, page-787

Not sure of an estimate, expenses are much harder to predict than sales. I think our friend @Counterfiat is spot on when he says that there will be another cap raise, though I don't share in his negative sentiment regarding that. This future raise will likely come when the share price is trading in the dollars and will be highly accretive for future growth. Due to the high price, the dilution should be minimal. If the price is still at 30c when we need to next raise, then we have a lot more to worry about than a cap raise

Expenses will likely go up in $ terms but I wouldn't be surprised if they fall as a % of sales. In that case, the net loss might actually be less than last year and this year, reducing the cash burn and therefore reducing risk of a cap raise in the near term. Higher expenses are a cost of high growth unfortunately, though it seems like a lot of past expenditure has been of a temporary nature, needed to establish the foundations to launch iTrack Advance. Marketing related expenditure will likely rise (I would be concerned if it doesn't), though this should be offset by reduced expenditure elsewhere.